MUKILTEO, Wash., Jan. 28, 2009 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) announced today that Leuchemix provided additional information regarding the initial clinical trial of its novel anticancer drug LC-1. The initial trial is being performed at Cardiff University in the United Kingdom under the supervision of Professor Alan Burnett.
